Please assess the completion status of the following clinical trial:

Trial Title: Randomized Clinical Trial of Bococizumab (PF-04950615; RN316) in Subjects Who Are Intolerant to Statins

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Hyperlipidemia~* Statin Intolerant~* Fasting LDL-C \> = 70 mg/dL Fasting TG \< = 400 mg/dL~Exclusion Criteria:~* Pregnant or breastfeeding females~* Cardiovascular or cerebrovascular event or procedure within 90 days~* Severe or life-threatening adverse events with past use of statins~* Poorly controlled hypertension

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Bococizumab (PF-04950615;RN316) (Type: EXPERIMENTAL): Bococizumab (PF-04950615;RN316)
- Atorvastatin (Type: ACTIVE_COMPARATOR): None
- Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).